Re: |
NeoStem, Inc. |
1. |
Please provide dates of discussion with RimAsia as disclosed in the last paragraph on page 86. |
Securities and Exchange Commission |
October 2, 2009 |
Page 2 |
2. |
On page 87 you mention “numerous telephone calls” involving terms and negotiating of definitive documents in the “spring and summer of 2008.” Please tell us whether these discussions and negotiations are detailed in the discussion. If not, please disclose dates, parties and material terms discussed. |
3. |
We note your response to comment six of our letter dated September 18, 2009. You list several discussions and negotiations without stating the terms discussed. For example, please provide the material terms discussed for the following: |
|
· |
The meetings with your bankers in May 2008 discussing “ranges of fair prices for the transactions” disclosed on page 86; |
|
· |
July 17 and 18, 2008 discussions regarding “[t]ransaction structure and accounting issues …” and terms of the security to be issued in exchange for such Series B Preferred Stock” disclosed on page 88; |
|
· |
The July 24, 2008 conference call regarding “deal structure” disclosed on page 88 |
|
· |
The September 4, 2009 memorandum discussing ““open structural issues” disclosed on page 88; |
|
· |
The revised and re-circulated agreement of Plan of Merger and Exchange Agreement discussed on page 88; |
|
· |
The October 15, 2008 conference call discussing deal terms, disclosed on page 88; and |
|
· |
The October 25, 2008 redistribution of documentation disclosed on page 88. |
Securities and Exchange Commission |
October 2, 2009 |
Page 3 |
4. |
We note your response to comment 11 of our letter dated September 18, 2009. In your discussion of the timeline in the “Background” discussion on page 113, please provide the date of the adoption of the final agreement of a frame of reference. |
5. |
We note your response to comments 12 and 17 of our letter dated September 18, 2009. You indicate in your response that vFinance was fully informed on the proposed changes in the aggregate consideration being paid in amendment No. 1 and No. 2 along with the terms of the transaction and that vFinance orally informed the company that the changes did not adversely
affect its view as to the fairness of the transactions to the shareholders of the company from a financial point of view. You also state in your letter that upon receipt of the reaffirmation from vFinance the company will close without further information being provided to investors prior to closing. You also state that if vFinance were unable to reconfirm the fairness of the transaction to NeoStem would either not close and abandon the transaction or resolicit shareholder approval, possibly
on amended terms. Please include these disclosures in your prospectus. |
Securities and Exchange Commission |
October 2, 2009 |
Page 4 |
|
· |
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; |
|
· |
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and |
|
· |
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. |
cc: |
Catherine M. Vaczy, Esq. |